Seelos Therapeutics Delisted From Nasdaq, Will Transition To OTC Market
Seelos Therapeutics, Inc. (NASDAQ:SEEL), a biopharmaceutical company developing treatments for central nervous system disorders and rare diseases, announced that it received a notice on October 14, 2024, from the Nasdaq Hearings Panel to delist its common stock.
This decision follows Seelos’ failure to meet the Nasdaq’s minimum stockholder equity requirement, despite an extension until October 11, …